Capital Increase / Dilution2026-05-27

Penetrium Bioscience Amends Capital Increase Schedule

PEN

페니트리움바이오

187660

-0.05

Signal Score

51CNeutral
Score51 / 100

Historical Avg Return (5d)

+0.15%

Data Coverage

100%n=2535

Risk-adjusted indicator based on 2535 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEUTRAL

Key Numbers

  • • New Share Allotment Record Date: June 16, 2026 (Changed from June 5, 2026)
  • • Old Shareholder Subscription Start Date: July 22, 2026 (Changed from July 9, 2026)
  • • Old Shareholder Subscription End Date: July 23, 2026 (Changed from July 10, 2026)
  • • Final Issue Price Determination Date: July 16, 2026 (Changed from July 6, 2026)
  • • Discount Rate for Issue Price Calculation: 25%

AI Analysis Summary

Penetrium Bioscience Inc. has filed an amendment to its Material Fact Report regarding a paid-in capital increase. The key changes involve a postponement of the new share allotment record date to June 16, 2026, and the old shareholder subscription period to July 22-23, 2026. The final issue price determination date has also been pushed to July 16, 2026. The issue price will be determined with a 25% discount rate. While the capital increase itself is dilutive, this amendment primarily concerns schedule adjustments, leading to a neutral financial impact.

How This Event Is Evaluated

Capital Raise Evaluation

Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.

AI is used to interpret disclosures and extract structured data.

Signal scores are generated using event-specific methodologies and quantitative models.

  • Potential dilution rate
  • Issuance or conversion price
  • Funding purpose
  • Shareholder value impact
Read our full scoring methodology →

Track Korean Market Signals — Free

Sign up free to access live disclosures, AI analysis, and event filters.

Public Beta · No credit card required

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: [기재정정]주요사항보고서(유상증자결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.